Overall , individuals allocated to alemtuzumab-based treatment had a @ % proportional reduction in biopsy-proven acute rejection compared with those allocated to basiliximab-based treatment ( @ -LSB- @ % -RSB- patients in the alemtuzumab group vs @ -LSB- @ % -RSB- patients in the basiliximab group ; hazard ratio ( HR ) @ , @ % CI @-@ ; log-rank p < @ ) .